INTRODUCTION
============

Lung cancer is the leading cause of cancer-related deaths, killing more than 1 million people every year worldwide ([@b28-bt-23-141]). Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer death in the world ([@b11-bt-23-141]; [@b18-bt-23-141]). For early-stage NSCLC, surgical resection is the treatment of choice ([@b11-bt-23-141]). The most common post-resection events leading to mortality are tumor recurrence and metastasis ([@b39-bt-23-141]).

Epithelial mesenchymal transition (EMT) in lung cancer arises during embryonic cell layer movements and tumor cell invasion ([@b6-bt-23-141]). An analysis of a large number of lung tumor specimens showed that the majority of primary lung cancer cells and even premalignant lesions have the mesenchymal phenotype, which is characterized by down-regulation of E-cadherin and up-regulation of N-cadherin ([@b30-bt-23-141]). During EMT, the epithelial protein E-cadherin is down-regulated, and the mesenchymal proteins vimentin and N-cadherin are up-regulated, via transcription factors that include snail, ZEB1, and ZEB2 ([@b29-bt-23-141]).

Cytokines of the transforming growth factor-β (TGF-β) family, meanwhile, have multiple roles in the development of diseases including cancer ([@b14-bt-23-141]). Perturbations of TGF-β signaling, for example, are central to tumorigenesis and tumor progression, specifically through their effects on cellular processes including cell proliferation and cell invasion ([@b12-bt-23-141]). In this way, TGF-β1 induces EMT in cancer cells, thereby enabling them to become motile and invasive ([@b16-bt-23-141]; [@b14-bt-23-141]; [@b26-bt-23-141]).

C-Jun N-terminal kinase (JNK) is a member of the family of mitogen-activated protein kinases (MAPK) that is well-known for its role in stress responses and apoptosis regulation ([@b5-bt-23-141]). Recent studies have uncovered evidence of JNK's possible role in TGF-β1-induced EMT ([@b2-bt-23-141]; [@b36-bt-23-141]). It appears that sustained JNK activity, by regulating extracellular signal-regulated kinase activation, promotes EMT, invasion and survival of breast cancer cells ([@b37-bt-23-141]). Recently, we found that transglutaminase-2 (Tgase-2) activated JNK by reduced expression of protein serine/threonine phosphatase 2A (PP2A) in TGF-β1-induced EMT ([@b26-bt-23-141]).

PP2A, is an abundant cellular enzyme with numerous substrates that modulates various cellular functions ([@b20-bt-23-141]). PP2A's catalytic subunit has the capacity to dephosphorylate serine and threonine residues ([@b7-bt-23-141]). The activities of several kinases, including JNK, are reduced by PP2A ([@b17-bt-23-141]).

Cardamonin (CDN, 2′,4′-dihydroxy-6′-methoxychalcone), a well-known component of *Alpinia Katsumadai* ([@b38-bt-23-141]; [@b24-bt-23-141]) has anti-tumor, anti-inflammatory, anti-itching, and anti-nociceptive activities ([@b4-bt-23-141]; [@b40-bt-23-141]; [@b23-bt-23-141]; [@b25-bt-23-141]). Studies have found that it inhibits the production of pro-inflammatory mediators in whole blood or human monocytes ([@b1-bt-23-141]; [@b8-bt-23-141]).

Several mechanism of actions of CDN were proposed to explain its diverse biological activities. For example, previous studies found that CDN inhibited mTOR, NF-κB, Wnt pathways ([@b27-bt-23-141]; [@b9-bt-23-141]; [@b35-bt-23-141]). Notably, we also reported that CDN blocks cancer cell migration by inhibiting the expression and activity of transglutaminase-2 (Tgase-2), an important target for cancer and inflammation ([@b15-bt-23-141]; [@b22-bt-23-141]; [@b24-bt-23-141]). We have also showed that N-cadherin expression is dependent on Tgase-2 in TGF-β1-induced EMT ([@b26-bt-23-141]). Therefore, it is necessary to determine if CDN suppresses Tgase-2 dependent N-cadherin expression during TGF-β1-induced EMT. Furthermore, it is not known whether CDN suppress the TGF-β1-induced EMT.

In the present study, we examined the effects of CDN on TGF-β1-induced EMT of A549 lung cancer cells and found that CDN inhibited Tgase-2 dependent N-cadherin expression during TGF-β1-induced EMT by restoring PP2A expression.

MATERIALS AND METHODS
=====================

Reagents
--------

RPMI1640 and fetal bovine serum (FBS) were obtained from WelGENE Inc. (Daegu, South Korea). TGF-β1 was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Mouse monoclonal anti- E-cadherin, and anti-PP2A antibodies were acquired from BD Biosciences (San Jose, CA, USA). Mouse monoclonal anti-β-Actin and rabbit polyclonal anti-N-cadherin antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anti-JNK, mouse monoclonal anti-phosphor-JNK and HRP-conjugated anti-mouse antibodies were purchased from Cell Signalling Technology, Inc. (Beverly, MA, USA).

Cell culture
------------

A549 (CCL-185), a human lung adenocarcinoma cell line, was obtained from the American Type Culture Collection. The A549 cells were cultured in RPMI 1640 medium supplemented with 10% FBS at 37°C in a humidified, 5% CO~2~ atmosphere.

Cell migration assay
--------------------

Migration assays were performed in a transwell (Neuro Probe, Inc., Gaithersburg, MD, USA) coated with 10 μg/mL fibronectin. A549 cells (1×10^6^ cells/mL) suspended in serum-free medium were added to the upper chamber of the transwell inserts. To the lower chamber, medium containing 3% FBS was added. After 5 h incubation, non-migrated A549 cells were scraped off the upper surface of the membrane; the migrated A549 cells on the lower surface were stained by Diff-quick and counted under four randomly chosen high-power fields (20× magnification). All of the experiments were repeated at least three times with two replicates each.

Cell-invasion assay
-------------------

A cell invasion assay was performed using matrigel-coated (0.5 μg/mL) transwell inserts, as described previously. A549 cells (1×10^6^ cells/mL) suspended in serum-free medium were added to the upper chamber of the transwell inserts. To the lower chamber, medium containing 10% FBS was added. After 16 h incubation, non-migrated A549 cells were scraped off the upper surface of the membrane; the cells on the lower surface were stained using the Hema 3 staining system (Fisher Scientific, Houston, TX, USA), photographed, and counted under four randomly selected fields (20× magnification). All of the experiments were repeated at least three times with two replicates each.

Western blot analysis
---------------------

After incubation, the A549 cells were collected and washed twice with cold phosphate-buffered saline (PBS). They were then lysed in a buffer \[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% tritonX-100, 2 mM EDTA, 1% DOC (Deoxycholic-acid), 0.1% SDS, 1 mM NaVO~3~, 10 mM NaF, 1 mM DTT\] and centrifuged to yield whole-cell lysates. The protein concentration was measured using the Bradford method. Aliquots of the lysates (20--30 μg of protein) were separated on 8--12% SDS-polyacrylamide gel and transferred onto a polyvinylidene fluoride (PVDF) membrane (Invitrogen, Carlsbad, CA, USA) with glycine transfer buffer \[192 mM glycine, 25 mM Tris-HCl (pH 8.8), 10% MeOH (v/v)\]. After blocking the non-specific site with 5% non-fat dry milk, the membrane was incubated with specific primary antibody in 3% bovine serum albumin (BSA) at 4°C overnight, and then further incubated for 60 min with a peroxidase-conjugated secondary antibody (1:5,000, Santa Cruz Biotechnology Inc.) at room temperature. Immunoreactive proteins were detected using PowerOpti-ECL Western blotting detection reagent (Animal Genetics Inc., Gyeonggi, Korea).

Reverse transcription polymerase chain reaction (RT-PCR)
--------------------------------------------------------

Total RNA extraction from A549 cells was conducted in an RNase-free environment by the Tri-Reagent method (Invitrogen), according to the manufacturer's instructions. Reverse transcription of 1 μg RNA was carried out using M-MuLV reverse transcriptase (Promega), oligo (dT) 15 primer, dNTP (0.5 μM) and 1 U RNase inhibitor. PCR was performed with an Applied Biosystems GeneAmp PCR system (Invitrogen); the amplification program included 30 cycles at 94°C (denaturing), 50--58°C (annealing) and 72°C (extension), respectively. The PCR products were electrophoresed on 1.2% agarose gel.

Confocal microscopy
-------------------

A549 cells grown on coverslips and fixed in methanol (MeOH) for 10 min at room temperature were permeabilized with a 10 min wash in 0.1% Triton X-100, also at room temperature, followed by several washes in PBS with 3% BSA. Phosphor-JNK and PP2A primary antibody were incubated with the A549 coverslips overnight at 4°C, after which the antibody was removed with four washes in PBS. Species-specific secondary antibodies conjugated in goat anti-mouse IgG antibody (Alexa Fluor 488, 1:500 Molecular Probes) were then reacted with the coverslips for 1 h at room temperature followed by four washes in PBS. The final samples were mounted onto slides and visualized under Nikon confocal microscopy.

Statistical analysis
--------------------

Data herein are expressed as the mean ± standard deviations (S.D.) of at least three independent experiments performed in triplicate. A student's *t*-test was used to analyze the data, according to the following significance levels: \**p*\<0.05, \*\**p*\<0.01.

RESULTS
=======

CDN suppressed TGF-β1-induced EMT in A549 lung cancer cell lines
----------------------------------------------------------------

EMT was induced in A549 lung adenocarcinoma cells by TGF-β1 (100 pM) treatment, according to the Lee's report ([@b18-bt-23-141]). TGF-β1 treatment of A549 cells induced the mesenchymal morphology, including loss of cell-to-cell contact, and CDN suppressed those mesenchymal changes ([Fig.1A](#f1-bt-23-141){ref-type="fig"}). TGF-β1 treatment also induced the mRNA expression of mesenchymal markers including N-cadherin and reduced the expression of epithelial markers such as E-cadherin, and induced the EMT-related transcription factors such as ZEB1 and snail1 ([Fig. 1B](#f1-bt-23-141){ref-type="fig"}). These results were confirmed by Western blot ([Fig. 1C](#f1-bt-23-141){ref-type="fig"}).

CDN suppressed TGF-β1-induced migration and invasion in A549 lung cancer cell lines
-----------------------------------------------------------------------------------

TGF-β1-induced Tgase-2 is involved in the EMT in A549 cells, leading to the migration and invasion of A549 cancer cells ([@b26-bt-23-141]). In a previous report, we showed that CDN suppresses the expression and activity of Tgase-2, leading to inhibition of HT1080 cell migration ([@b24-bt-23-141]). Therefore, we examined the effects of CDN on the migration and invasion of A549 cancer cell lines. We found that TGF-β1 induced enhanced migration and invasion in A549 lung cancer cells and that CDN dose-dependently suppressed such migration and invasion ([Fig. 2](#f2-bt-23-141){ref-type="fig"}).

CDN suppressed JNK activation in TGF-β1-induced EMT of A549 lung cancer cell lines
----------------------------------------------------------------------------------

In another previous report, we showed that JNK is activated in TGF-β1-induced EMT, and thus leads to N-cadherin expression ([@b26-bt-23-141]). So, we investigated, in the present study, whether CDN suppresses TGF-β1-induced JNK activation. According to our results, TGF-β1 treatment induced phosphorylation of JNK (active JNK), and CDN dose-dependently suppressed JNK activation ([Fig. 3A](#f3-bt-23-141){ref-type="fig"}). This was confirmed by confocal microscopy ([Fig. 3B](#f3-bt-23-141){ref-type="fig"}).

CDN restored PP2A expression in TGF-β1-induced EMT of A549 lung cancer cell lines
---------------------------------------------------------------------------------

PP2A dephosphorylated phospho-JNK (active form) to dephosphorylated JNK (inactive form) ([@b10-bt-23-141]). Thus we examined whether PP2A is involved in CDN's effects on EMT. To that end, PP2A expression was reduced in TGF-β1-induced EMT ([Fig. 4A](#f4-bt-23-141){ref-type="fig"}). The results showed that CDN restored PP2A expression in TGF-β1-induced EMT ([Fig. 4A](#f4-bt-23-141){ref-type="fig"}). Confocal microscopy data confirmed this observation ([Fig. 4B](#f4-bt-23-141){ref-type="fig"}).

DISCUSSION
==========

EMT is an important early step in metastasis of cancer cells ([@b13-bt-23-141]; [@b33-bt-23-141]; [@b31-bt-23-141]). EMT is also implicated in the phenotype of cancer stem cells ([@b3-bt-23-141]), therefore understanding and controlling EMT is essential to the prevention of metastasis.

[Fig. 1](#f1-bt-23-141){ref-type="fig"} and [2](#f2-bt-23-141){ref-type="fig"} show that CDN inhibits TGF-β1-induced expression of N-cadherin and migration and invasion of A549 cancer cells. [Fig. 3](#f3-bt-23-141){ref-type="fig"} shows that TGF-β1 induced JNK activation, which is inhibited by CDN. Previous research has demonstrated that TGF-β1-induced JNK activation is dependent on Tgase-2 ([@b26-bt-23-141]). These results suggest that CDN might suppress N-cadherin expression, migration and invasion via Tgase-2 inhibition-based mechanism ([@b24-bt-23-141]; [@b23-bt-23-141]; [@b25-bt-23-141]).

Recently, several reports have indicated that JNK activation is involved in EMT ([@b37-bt-23-141]; [@b26-bt-23-141]; [@b19-bt-23-141]). JNK is activated by MAP kinase pathway or by PP2A reduction ([@b41-bt-23-141]; [@b26-bt-23-141]). Reduction of PP2A expression by Tgase-2 contributes to JNK activation, since PP2A plays a key role in inactivating JNK ([@b26-bt-23-141]). Correspondingly, in the present study, CDN restored PP2A expression in TGF-β1-treated A549 cancer cells ([Fig. 4](#f4-bt-23-141){ref-type="fig"}).

Based on these results, Tgase-2 inhibition should be added to other proposed mechanism of action of CDN including mTOR, NF-κB, and WNT pathways responsible for its diverse biological activities ([@b24-bt-23-141]; [@b27-bt-23-141]; [@b9-bt-23-141]; [@b35-bt-23-141]). It should be noted that phosphorylation and dephosphorylation are key steps in several of the suggested mechanism of action of CDN, including the previously mentioned pathways. We speculated that CDN-induced PP2A restoration via Tgase-2 inhibition lead to the suppression of several key kinases in mTOR, NF-κB, and WNT pathway. However, it is still unclear how Tgase-2 inhibition leads to PP2A restoration.

Recently, special attention has been centered on drugs that restore or activate PP2A in cancer cells ([@b32-bt-23-141]; [@b21-bt-23-141]). FTY720 activated PP2A via binding to protein SET, a PP2A inhibitory protein ([@b32-bt-23-141]), and a dithiolethione compound inhibited AKT signaling in human breast and lung cancer cells by increasing PP2A activity ([@b34-bt-23-141]). According to the present research findings, CDN could be considered as a PP2A-restoration compound.

In the present study, we found that CDN inhibited N-cadherin expression and restored PP2A expression via Tgase-2 inhibition, which suppresses TGF-β1-induced EMT that is critical to metastasis. Tgase-2 inhibition might be new way of restoring PP2A, and CDN appears to have potential as an antimetastatic compound.
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![CDN inhibited TGF-β-induced EMT in A549 cells. (A) Phase-contrast images of A549 cells. Cells were pre-treated with CDN (1, 5 and 10 μM) for 1h. Next, they were treated with TGF-β1 (100 pM). After 48 h, the cells were photographed using a real-time image system under Leica microscopy (20× magnification). (B) Immunoblot analysis of E-cadherin, N-cadherin and transglutaminase-2 (Tgase-2) in A549 cells treated with CDN (1, 5 and 10 μM) and TGF-β1 (100 nM) for 48h. The β-Actin was used here as an internal control. (C) Reverse transcription-PCR of E-cadherin and N-cadherin in A549 cells treated with CDN (1, 5 and 10 μM) and TGF-β1 (100 nM) for 48 h.](BT-23-141f1){#f1-bt-23-141}

![CDN inhibited migration and invasion by TGF-β-induced EMT in A549 cells. (A) Effects of CDN on TGF- β1-induced cell migration. For the migration assay, lower-chamber transwells were coated with fibronectin (10 μg/ml). (B) Effects of CDN on TGF-β1-induced cell invasion. For the invasion assay, lower-chamber transwells were coated with matrigel (0.5 μg/ml). The data represent the means ± S.D. of three wells. \**p*\<0.05, \*\**p*\<0.01 compared with TGF- β1-treated group.](BT-23-141f2){#f2-bt-23-141}

![CDN inhibited TGF-β-induced phosphorylation of JNK in A549 cells. (A) Immunoblot analysis of phosphor-JNK and JNK in A549 cells treated with CDN (1, 5 and 10 μM) and TGF-β1 (100 nM) for 48 h. β-Actin was used here as an internal control. (B) Confocal microscopic examination of phosphor-JNK (60× magnification).](BT-23-141f3){#f3-bt-23-141}

![CDN induced PP2A expression reduced by TGF-β1 in A549 cells. (A) Immunoblot analysis of PP2A in A549 cells treated with CDN (1, 5 and 10 μM) and TGF-β1 (100 nM) for 48 h. β-Actin was used here as an internal control. (B) Confocal microscopic examination of PP2A (60× magnification).](BT-23-141f4){#f4-bt-23-141}
